Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3

Qiao,Haishi; Zhao,Dan; Shi,Hengfei; Ren,Ke; Li,Jianxin; Li,Erguang

doi:10.3892/or.2015.4140

Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3

Authors:
- Haishi Qiao
- Dan Zhao
- Hengfei Shi
- Ke Ren
- Jianxin Li
- Erguang Li
View Affiliations

Affiliations: Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, Jiangsu 210093, P.R. China, School of Chemistry and Chemical Engineering and State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, Jiangsu 210093, P.R. China, Jiangsu Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu 210093, P.R. China
Published online on: July 21, 2015 https://doi.org/10.3892/or.2015.4140
Pages: 1875-1882

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Quinazoline core-containing compounds such as gefitinib and erlotinib constitute an important group of antitumor drugs that act as receptor tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) kinase activity. We investigated a group of recently prepared 2-alkyl-substituted quinazolines (2-ASQs) for their antitumor activity against non-small cell lung carcinoma (NSCLC) cells. The compounds showed antitumor activity against A549, H1299, and H460 cells by induction of apoptosis. The IC50 values for (E)-2-propyl-4-styrylquinazoline (compound #4) and (E)-2‑cyclopropyl-4-styrylquinazoline (compound #7) against these cell lines were 2-5 times lower than that of gefitinib. Unlike gefitinib that blocks EGFR phosphorylation, these compounds showed no activity against EGFR activation. Instead, the compounds suppressed both constitutive and IL-6-induced activation of JAK2/STAT3 phosphorylation and downstream gene expression. Transient expression of a constitutively active mutant of STAT3 reversed the pro-apoptotic effect of compound #7. Using a nude mouse model bearing A549 xenografts, we showed that administration of #7 at 15 and 30 mg/kg suppressed tumor growth. The present study therefore demonstrated that 2-alkyl substituted quinazolines target the JAK2/STAT3 pathway for their antitumor activity.

View Figures

View References

1	Herbst RS, Fukuoka M and Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer. 4:956–965. 2004. View Article : Google Scholar : PubMed/NCBI
2	Wheeler DL, Dunn EF and Harari PM: Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol. 7:493–507. 2010. View Article : Google Scholar : PubMed/NCBI
3	Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
4	Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:127–137. 2002. View Article : Google Scholar : PubMed/NCBI
5	Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:4292–4302. 2002. View Article : Google Scholar : PubMed/NCBI
6	Scagliotti GV, Selvaggi G, Novello S and Hirsch FR: The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 10:4227s–4232s. 2004. View Article : Google Scholar : PubMed/NCBI
7	Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G and Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 74:1253–1257. 1996. View Article : Google Scholar : PubMed/NCBI
8	Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y and Sugimachi K: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol. 3:109–113. 1994. View Article : Google Scholar : PubMed/NCBI
9	Robertson SC, Tynan J and Donoghue DJ: RTK mutations and human syndromes: When good receptors turn bad. Trends Genet. 16:3682000. View Article : Google Scholar : PubMed/NCBI
10	Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al Spanish Lung Cancer Group: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
11	Robinson KW and Sandler AB: EGFR tyrosine kinase inhibitors: Difference in efficacy and resistance. Curr Oncol Rep. 15:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhong D, Ru Y, Wang Q, Zhang J, Zhang J, Wei J, Wu J, Yao L and Li X and Li X: Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling. Cancer Lett. 359:57–64. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Pan J, Dong Y, Tweardy DJ, Dong Y, Garibotto G and Mitch WE: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 18:368–379. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Puri PL, Latella L and Sacco A: STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 20:1182–1186. 2014. View Article : Google Scholar : PubMed/NCBI
15	Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur C, Sun J, Li L, Kowluru A and Chen F: Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget. 4:2430–2438. 2013.PubMed/NCBI
17	Zhao D, Zhu MX, Wang Y, Shen Q and Li JX: Pd(0)-catalyzed benzylic arylation-oxidation of 4-methylquinazolines via sp³ C-H activation under air conditions. Org Biomol Chem. 11:6246–6249. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhao D, Wang T, Shen Q and Li JX: n-Bu₄NI-catalyzed selective dual amination of sp³ C-H bonds: Oxidative domino synthesis of imidazo[1,5-c]quinazolines on a gram-scale. Chem Commun. 50:4302–4304. 2014. View Article : Google Scholar
19	Zhang L, Gao Z, Peng C, Bin ZY, Zhao D, Wu J, Xu Q and Li JX: Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives. Mol Divers. 16:579–590. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhao D, Shen Q, Zhou YR and Li JX: KOtBu-mediated stereose-lective addition of quinazolines to alkynes under mild conditions. Org Biomol Chem. 11:5908–5912. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang D and Gao F: Quinazoline derivatives: Synthesis and bioactivities. Chem Cent J. 7:952013. View Article : Google Scholar : PubMed/NCBI
22	Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
23	Harada D, Takigawa N and Kiura K: The role of STAT3 in non-small cell lung cancer. Cancers. 6:708–722. 2014. View Article : Google Scholar : PubMed/NCBI
24	Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G and Aggarwal BB: Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res. 5:943–955. 2007. View Article : Google Scholar : PubMed/NCBI
25	Bharti AC, Donato N and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
26	Baskin R, Majumder A and Sayeski PP: The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Curr Med Chem. 17:4551–4558. 2010. View Article : Google Scholar : PubMed/NCBI
27	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
28	Yang SH, Khadka DB, Cho SH, Ju HK, Lee KY, Han HJ, Lee KT and Cho WJ: Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorg Med Chem. 19:968–977. 2011. View Article : Google Scholar
29	LaPorte MG, da Paz Lima DJ, Zhang F, Sen M, Grandis JR, Camarco D, Hua Y, Johnston PA, Lazo JS, Resnick LO, et al: 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorg Med Chem Lett. 24:5081–5085. 2014. View Article : Google Scholar : PubMed/NCBI
30	Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
31	Engelman JA and Jänne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI